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Introduction
Finasteride is used primarily to relief symptoms from 
benign prostatic hyperplasia (5 mg pills) and to treat 
androgenetic alopecia (1 mg pills). Finasteride inhibits 
the type 2 5α- reductase enzyme, thereby inhibiting the
conversion of testosterone to dihydrotestosterone, leading 
to shrinkage of androgen- dependent prostate tissue [1]. 
Use of finasteride increases estradiol levels, which may 
cause gynecomastia [2]. Increased estradiol levels caused 
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Abstract
A potential link has been suggested between dispensed finasteride and increased 
risk of male breast cancer (MBC). Due to the rare occurrence of MBC, it 
 remains to be established if such a relationship exists. The purpose of this study 
was to combine nationwide registers in four countries to assess the potential 
association between dispensed finasteride and MBC. A cohort of all males with 
dispensed finasteride in Denmark, Finland, Norway, and Sweden (1,365,088 
person years) was followed up for up to 15 years for breast cancer, and com-
pared to a cohort of males unexposed to finasteride. Individual- level register 
data included country, dates of dispensed finasteride, MBC diagnosis, and death. 
Incidence rate ratios (IRRs) were estimated using a generalized linear model 
with a Poisson distribution. An increased risk of MBC was found among fin-
asteride users (IRR = 1.44, 95% confidence interval [95% CI] = 1.11–1.88) 
compared to nonusers. The IRR increased to 1.60 (95% CI = 1.20–2.13) when 
users in Norway and Sweden with short follow- up time were excluded. The 
highest IRR was seen among men with medium duration of dispensed finas-
teride, medium accumulated consumption of finasteride, and among men with 
first dispensed finasteride prescription 1–3 years prior to diagnosis. The analyses 
suggested possible ascertainment bias and did not support a clear relationship 
between dispensed finasteride and MBC. In conclusion, a significant association 
between dispensed finasteride and MBC was identified. However, due to limited 
data for adjustment of potential confounding and surveillance bias in the present 
study, further research is needed to confirm these results.
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by finasteride have raised concerns about a possible link 
between finasteride use and male breast cancer (MBC) 
[3–8]. In a cross- national study in Denmark, Finland, 
Norway, and Sweden, dispensed finasteride was estimated 
at 10.8 per 1000 men in 2009 [9].
A review found 50 spontaneously reported MBC cases 
worldwide in patients treated with 5 mg finasteride and 
three reports in patients treated with 1 mg finasteride 
[6]. The median time to onset of MBC after starting 
5 mg finasteride treatment was 36 months (range: 5 weeks 
to 11 years). The review identified eight cases that were 
observed in three placebo- controlled clinical trials [4, 5, 
8], where individuals were exposed to 5 mg finasteride 
and followed up for up to 5 years, altogether for 89,496 
person years (PY). The crude incidence rate of MBC in 
persons treated with finasteride was 7.8 per 100,000 PY 
(95% confidence interval [95% CI] = 3.7–16.4), which 
was higher although not statistically different from the 
MBC rate 3.8 per 100,000 PY (95% CI = 1.2–11.9) in 
the unexposed group (P = 0.33). On this basis, the review 
concluded that it could not be excluded that finasteride 
could be associated with an increased risk of MBC [6]. 
Two recent studies found no significant association between 
finasteride use and MBC [10, 11].
MBC is a rare disease with a reported age- adjusted 
incidence rate of 0.4–1.0 per 100,000 PY in Europe [12–14]. 
Investigating the possible link between finasteride use and 
MBC is challenging due to the combination of a limited 
number of MBC cases [15–22], potential surveillance bias 
due to the association between finasteride use and breast 
enlargement and tenderness, and confounding from obesity, 
alcohol intake, liver disease, and family history [23]. The 
objective of this study was to investigate if an association 
exists between dispensed finasteride and MBC incidence 
in Denmark, Finland, Norway, and Sweden using register 
data containing all dates and amounts of finasteride 
redeemed from pharmacies.
Methods
Study design
A register- based cohort study with prospective data col-
lection was used including all males in Denmark, Finland, 
Norway, and Sweden. Dispensed finasteride was the 
exposure variable and MBC diagnosis the study outcome. 
In this study, the term dispensed finasteride means that 
finasteride has been purchased and handed out to the 
patient. The incidence rate of MBC was compared 
between an exposed cohort of all men in the four Nordic 
countries having redeemed finasteride and a cohort of 
all men in the Nordic countries unexposed to 
finasteride.
Data sources and study period
Data were extracted from the national prescription, cancer, 
and cause of death registers in the four countries. All 
redeemed prescriptions of finasteride were extracted for 
1995–2009 in Denmark, 1997–2010 in Finland, 2004–2009 
in Norway, and 2005–2009 in Sweden where finasteride 
is a prescription- only medicine. The Anatomic Therapeutic 
Classification (ATC) code is D11AX10 for 1 mg finasteride 
and G04CB01 for 5 mg finasteride (in Finland in 1994–1996, 
5 mg finasteride was registered as ATC G04CB04 and 
was not included in the study). During the study period, 
1 mg finasteride tablets were sold only in Denmark and 
Sweden. All inhabitants in the Nordic countries have a 
unique personal identification code (PIC), which facilitate 
linkage of individual- level register data. The PIC is given 
at birth or immigration, and is used as the identification 
key in the national registers. Individual information on 
dates of MBC diagnoses was extracted from national cancer 
registers. Only the first male breast cancer tumor was 
included. Individual information on date of death was 
extracted from the national cause of death registers.
Information for the general populations on the number 
of MBC cases and the size of the population was obtained 
from the NORDCAN database for each country and cal-
endar year (1995, 1996, …, 2010) stratified by 5- year age 
groups (0–4, 5–9, 10–14, …, 80–84, ≥85 years) [21]. 
NORDCAN is a Nordic database and program on the 
incidence, prevalence, mortality, and survival statistics from 
50 major cancers in the Nordic countries. Data in each 
of the Nordic countries are available for more than five 
decades. NORDCAN provides access to summary data 
with graphic and tabulation facilities.
Measures
The exposed cohort consisted of all men with a dispensed 
finasteride prescription in the study period. Individual- 
level data were obtained for the exposed cohort from the 
prescription registers including information on PIC, date 
of dispensed finasteride prescription, age of the recipient 
number of packages purchased, pills per package, and 
dose per pill. These data were linked with individual 
information on dates of MBC diagnoses from national 
cancer registers and with individual information on date 
of death from the national cause of death registers. For 
the exposed cohort, follow- up started on the date of the 
first dispensed finasteride. End of follow- up was the date 
of first MBC diagnose, date of death, date of emigration, 
or end of the study (31 December 2009 in Denmark, 
Norway, and Sweden, and 31 December 2010 in Finland), 
whichever came first. The number of PY and number of 
men with MBC in the exposed cohort were calculated in 
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5- year age groups (i.e., 0–34, 35–39, 40–44, …, 80–84, 
≥85 years), country, and calendar year.
The unexposed cohort was established as the difference 
between the general population and the exposed cohort. 
This was done by calculating PY in the unexposed cohort 
as the difference between the size of the general popula-
tion and the PY in the exposed cohort by each 5- year 
age group (i.e., 0–34, 35–39, 30–44, …, 80–84, ≥85 years), 
country, and calendar year. Hereby, men with a dispensed 
finasteride prescription contributed with nonexposed risk 
time before date of first dispensed finasteride prescription 
and with exposed risk time from first dispensed finasteride 
prescription. The number of men with MBC in the unex-
posed cohort was calculated as the difference between 
number of MBC in the general population and the exposed 
cohort.
Having ever redeemed finasteride was the primary expo-
sure variable. Supplementary analyses of finasteride expo-
sure were performed evaluating duration of exposure, 
cumulative dose, and time since first exposure. The cut- off 
values for duration of finasteride exposure, dose, and time 
since first finasteride exposure were decided prior to analysis 
in consultation with specialists.
Statistical analyses
The primary analysis investigated the association between 
having ever redeemed finasteride and the incidence rate 
of MBC among all men in the four countries and strati-
fied by country. The interactions between age group at 
follow- up and dispensed finasteride and between country 
and dispensed finasteride were evaluated. Further analyses 
on data from Denmark and Finland (with long follow- up 
time) were performed evaluating the effect of duration 
of exposure, cumulative dose, and time since first expo-
sure. The analyses were repeated after removing individuals 
with their first dispensed finasteride prescription in the 
first year of follow- up (i.e., 1995 for Denmark and 1997 
for Finland) to account for potential truncation bias (i.e., 
individuals with dispensed prescription in the first year 
might be prevalent users and the cumulative exposure 
cannot be correctly calculated).
All analyses were performed using a piecewise expo-
nential model for survival data. The analysis was performed 
using a generalized linear model with a Poisson distribu-
tion of number of MBC cases and logarithmic transfor-
mation of risk time as offset value. Adjustment was made 
for age, calendar year, and country as fixed effects. Constant 
incidence rates within intervals of time were obtained by 
splitting the risk time for each country, 5- year age group, 
and calendar year using the SAS Lexis macro [24]. The 
incidence rate ratios (IRRs) of MBC for the exposed 
compared to the nonexposed and 95% CI were calculated. 
All analyses were performed using the PROC GENMOD 
procedure of SAS version 9.3 (SAS Institute Inc., Cary, 
NC).
Sample size calculation
The minimum detectable IRR for MBC comparing fin-
asteride exposed to nonexposed was calculated at 2.6 and 
1.9, respectively, assuming a total population of approxi-
mately 12 mill men, 10.8 per 1000 men exposed to fin-
asteride, an incidence rate (IR) of MBC among nonexposed 
at 0.4 and 1 per 100,000 PY, respectively, 15 years follow-
 up, a 5% significance level, and a power of 80% [25].
Results
During follow- up, a total of 902 MBC cases occurred in 
112 million PY in the male population in Denmark, 
Finland, Norway, and Sweden (Table 1). This corresponded 
to a crude IR of 0.80 MBC cases per 100,000 PY (Table 1). 
The IR per 100,000 varied between 0.92 in Denmark and 
0.66 in Finland. The maximal follow- up time in the four 
countries was 15, 14, 6, and 5 years in Denmark, Finland, 
Norway, and Sweden, respectively. Median time from 
initiation of finasteride use to MBC diagnosis was 
40 months based on 55 MBC cases in Denmark and 
Finland with long follow- up time.
In the last year of follow- up, the PY among finasteride 
users accounted for 1.1% in Denmark, 1.4% in Sweden, 
3.0% in Finland, and 0.7% in Norway out of PY in the 
total male populations (Fig. S1). During the study period, 
finasteride users of 5 mg packages constituted 89% of 
the PY among finasteride users in Denmark and 90% in 
Sweden in 2009.
A total of 63 men developed MBC after dispensed fin-
asteride: 29 in Denmark, 26 in Finland, 1 in Norway, 
and 7 in Sweden (Table 2). There was a significantly 
increased incidence of MBC among finasteride users com-
pared to nonusers with an IRR of 1.44 (95% CI = 1.11–
1.88, P = 0.009). The IRR for dispensed finasteride increased 
to 1.60 (1.20–2.13) for the analysis of Denmark and Finland 
with long follow- up time. The country- specific IRR was 
highest in Denmark (IRR = 1.81, 95% CI = 1.23–2.67, 
P = 0.006). There was no significant interaction between 
country and dispensed finasteride (P = 0.18 for interac-
tion term). The association between dispensed finasteride 
and MBC was modified by age at follow- up with IRR at 
5.58 (95% CI = 3.14–9.92) for age<70 years at follow- up 
decreasing to 1.67 and 1.15 for age 70–79 years and 
≥80 years at follow- up, respectively (Table 2). When 
restricting the exposed group to finasteride users with 
5 mg finasteride, a significant association was found 
(IRR = 1.60, 95% CI = 1.20–2.14).
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Further analyses of Denmark and Finland showed that 
the risk of MBC was highest among men who redeemed 
finasteride up to 3 years (IRR = 1.89, 95% CI = 1.37–2.60) 
and among men whose accumulated consumption cor-
responded to up to three finasteride packs with 98 pills 
of 5 mg (IRR = 1.92, 95% CI = 1.33–2.79) (Table 3). 
The relative risk of MBC in finasteride users was highest 
during the follow- up period of 1–3 years after first dis-
pensed finasteride prescription (IRR = 2.28, 95% 
CI = 1.42–3.67), but not markedly lower during the first 
and fourth to fifth years of follow- up (Table 3). The 
effect of duration of dispensed finasteride, accumulated 
Table 1. Number of male breast cancer cases (NMBC), number of person years (NPY), and crude and age- standardized (Nordic Standard Population, 
2000) incidence rate of MBC (IR) per 100,000 in 1995–2010 overall and stratified by country, calendar period, and age group.
Variable Level NMBC NPY
IR per 100,000
Crude Age standardized
Overall 902 112,425,969 0.80 0.91
Country Denmark 365 39,844,762 0.92 1.08
Finland 236 35,834,189 0.66 0.74
Norway 101 14,011,628 0.72 0.82
Sweden 200 22,735,390 0.88 0.89
Year 1995–1998 116 15,424,184 0.75 0.98
1999–2002 165 20,691,378 0.80 0.96
2003–2006 303 36,821,669 0.82 0.90
2007–2010 318 39,488,738 0.81 0.85
Age group 0–34 9 50,567,403 0.02 –
35–39 14 8,288,627 0.17 –
40–44 22 8,402,741 0.26 –
45–49 33 8,120,563 0.41 –
50–54 56 8,034,841 0.70 –
55–59 85 7,512,897 1.13 –
60–64 117 6,496,764 1.80 –
65–69 117 4,915,216 2.38 –
70–74 148 3,882,216 3.81 –
75–79 116 2,964,162 3.91 –
80–84 99 1,943,265 5.09 –
≥85 86 1,296,790 6.63 –
Table 2. Association between dispensed finasteride and male breast cancer (MBC) in Denmark, Finland, Norway, and Sweden given by MBC cases, 
person years, P- value, incidence rate ratio (IRR), and 95% confidence interval (95% CI) adjusted for differences in age, calendar year, and country.
Finasteride 
exposure Cancer cases Person years Overall P- value IRR 95% CI
Primary analysis User 63 1,365,088 0.009 1.44 1.11–1.88
Nonuser 839 111,060,881 1 (ref)
Age group at follow- up
0–69 years User 12 519,340 <0.001 5.58 3.14–9.92
Nonuser 441 101,820,197 1 (ref)
70–79 years User 30 511,253 1.67 1.14–2.44
Nonuser 234 6,335,125 1 (ref)
≥80 years User 21 334,494 1.15 0.73–1.81
Nonuser 164 2,905,560 1 (ref)
Country specific
Denmark User 29 379,540 0.006 1.81 1.23–2.67
Nonuser 336 39,465,222 1 (ref)
Finland User 26 712,941 0.10 1.45 0.95–2.23
Nonuser 210 35,121,248 1 (ref)
Norway User 1 59,605 0.51 0.55 0.08–3.94
Nonuser 100 13,952,023 1 (ref)
Sweden User 7 213,002 0.92 0.96 0.45–2.06
Nonuser 193 22,522,388 1 (ref)
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dispensed finasteride prescriptions, and years after first 
dispensed finasteride prescription did not change when 
individuals with their first dispensed finasteride prescrip-
tion in the first year of the prescription registers were 
excluded (Table 3).
Discussion
In this population- based register study, we found a sta-
tistically significant 44% increased risk of MBC among 
men having finasteride prescribed compared to nonusers. 
The IRRs were highest for males in Denmark and Finland, 
that is, countries with longest follow- up period. The IRRs 
were highest in the categories of medium duration or 
lowest dose of finasteride which is against a causality of 
the association. An excess risk was identified in the first 
year after the first known dispensed finasteride and it 
decreased after 5 years. Such a short time lag and a 
decreasing risk over time are not typical in cancer causa-
tion. If the relative risk was first nonelevated and then 
increased after some years, it could be a sign of causal 
relation.
The main strength of this study is that it includes the 
largest number of persons exposed to finasteride reported 
yet. It has relatively long maximum follow- up time espe-
cially for the Danish and Finnish cohorts, and contains 
information for the total population and individual- level 
register data collected independently of the research ques-
tion. The quality of the prescription and cancer registers 
is high due to the completeness and validity of registered 
data [26–29].
There are some study limitations to be considered. First, 
exposure data were based on dispensed finasteride and 
not finasteride consumption. Exposure may therefore be 
overestimated, and the found association between dispensed 
finasteride and MBC may as a consequence be underes-
timated. Second, due to the rarity of MBC, the statistical 
power is limited. Third, surveillance bias may have influ-
enced the results because physicians may follow men with 
dispensed finasteride more closely or because of breast 
complaint and development of gynecomastia may lead to 
closer surveillance of users than nonusers. The finding of 
higher risk of breast cancer among short- term finasteride 
users could be a reflection of surveillance bias. Fourth, 
information about dispensed finasteride before establish-
ment of the prescription registers was not available. 
Therefore, the analyses accounting for “years after first 
dispensed finasteride prescription,” “cumulative dose,” and 
“duration of dispensed finasteride” underestimate the asso-
ciation. However, excluding finasteride users dispensed in 
the first year of data collection, as we do in Table 3, in 
principle corrects for this error. Fifth, the number of per-
sons followed up for longer time periods is still quite 
small and hence the power of the study to reveal possible 
Table 3. Association between dispensed finasteride, duration of dispensed finasteride, dose, and time since first dispensed finasteride prescription 
and male breast cancer (MBC) in Denmark and Finland given by MBC cases, risk time, P- value, incidence rate ratio (IRR), and 95% confidence interval 
(95% CI). Results are adjusted for differences in age, calendar year, and country.
Exposure 
categories
Including finasteride users with dispensed finasteride in first year 
of follow- up
Excluding finasteride users with dispensed finasteride in first 
year of follow- up
Cancer 
cases Person years
Overall 
P- value IRR 95% CI
Cancer 
cases Person years
Overall 
P- value IRR 95% CI
Dispensed finasteride
User 55 1,092,481 0.002 1.60 1.20–2.13 33 793,483 0.10 1.37 0.95–1.96
Nonuser 546 74,586,470 1 (ref) 535 69,800,789 1 (ref)
Duration of dispensed finasteride (years)
Nonuser 546 74,586,470 0.001 1 (ref) 535 69,800,789 0.09 1 (ref)
≤3 42 732,084 1.89 1.37–2.60 27 567,664 1.60 1.08–2.37
3.1–5 8 145,399 1.71 0.84–3.45 4 103,046 1.25 0.46–3.35
>5 5 214,998 0.66 0.27–1.60 2 122,773 0.48 0.12–1.95
Dose (categorized as number of finasteride packs with 98 pills of 5 mg)
Nonuser 546 74,586,470 0.007 1 (ref) 535 69,800,789 0.14 1 (ref)
≤3 30 528,958 1.92 1.33–2.79 21 415,570 1.76 1.13–2.74
3.1–6 9 161,739 1.80 0.92–3.50 3 120,040 0.82 0.26–2.56
>6 16 401,784 1.15 0.69–1.91 9 257,873 1.04 0.53–2.02
Time since first finasteride purchase (years)
Nonuser 546 74,586,470 0.01 1 (ref) 535 69,800,789 0.15 1 (ref)
<1 8 159,670 1.85 0.92–3.73 5 128,835 1.41 0.58–2.42
1–2.9 18 271,837 2.28 1.42–3.67 13 215,122 2.09 1.20–3.65
3–4.9 11 219,610 1.62 0.89–2.95 7 169,236 1.37 0.65–2.90
5+ 18 441,363 1.16 0.72–1.87 8 280,290 0.85 0.42–1.73
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role of finasteride as a cancer initiator is limited. If the 
finasteride would act as a moderator in the cancer process, 
then the lag from exposure to outcome is essentially shorter.
Most important limitation is the lack of data on poten-
tial confounding factors. Factors influencing the estrogen/
testosterone balance, including testicular abnormality, 
benign breast disease, gynecomastia, estrogen therapy, 
occupational exposures, and physical inactivity, obesity, 
family history of breast cancer, and comorbidities such 
as liver disease and alcohol intake, can be associated with 
both dispensed finasteride and MBC thereby confounding 
the observed association [18, 23].
The crude incidence rate of MBC estimated in the 
present study at 0.8 per 100,000 PY is within the range 
0.4–1.0 per 100,000 PY reported in earlier epidemiological 
studies [12–14]. The median time from initiation of fin-
asteride use to MBC diagnosis was 40 months in the 
present study. This is in accordance with previous studies, 
for example, MHRA reported a median time at male 
breast cancer developing 36 months after starting treat-
ment with 5 mg finasteride for enlarged prostate [6, 7].
Conflicting results are seen for the association between 
finasteride use and MBC from the few published studies 
in this area. A number of studies have indicated a possible 
link between finasteride use and risk of MBC [3, 5–8]. 
Bird et al. (2013) reported no significant association, but 
the follow- up time was only 1–3 years after exposure [10]. 
This is considered a short follow- up period. Duijnhoven 
et al. estimated a nonsignificant OR at 1.08 for the asso-
ciation between ever use of finasteride or dutasteride, but 
an OR at 1.29 for cumulative use for 3 or more years 
which is similar to the effect of cumulative use for 3–5 years 
in the present study with an IRR at 1.25 [11].
Only few observational epidemiological studies have been 
performed and the estimated association between finasteride 
use and MBC varies between these studies. In general, the 
Nordic prescription databases constitute an outstanding 
resource for pharmacoepidemiological studies in large popu-
lations [30], and pharmacoepidemiological studies in the 
Nordic countries are considered to have high validity [31].
We conclude that this study showed a significant increased 
risk of MBC among men having finasteride prescribed com-
pared to nonusers. The IRRs were highest for males in 
Denmark and Finland, that is, countries with longest follow-
 up period. Due to limited data for adjustment of potential 
confounding, more research is warranted to confirm the 
results. AG and ME declare: They have received finance 
from Merck Sharp & Dohme Corp. for the submitted work.
Conflicts of Interest
MM, LCT, KBr, PI, EP, KBo, KS, and AKE declare: no 
conflict of interest. AG and ME declare: They have received 
finance from Merck Sharp & Dohme Corp. for the sub-
mitted work. They declare no other relationships or activi-
ties that could appear to have influenced the submitted 
work. This article is based on data from a study conducted 
by Applied Economics and Health Research (ApEHR) as 
an independent research organization based on a regula-
tory request from the European Medicines Agency (EMA) 
and funded by Merck Sharp & Dohme Corp (MSD). MSD 
has had the opportunity to comment on the manuscript, 
but the authors retained the right to accept or reject 
comments and suggestions.
References
 1. Wilt, T. J., M. Roderick, H. Karen, S. Paul, T. James, 
R. S. Mark, et al. 2010. 5- alpha- Reductase inhibitors for 
prostate cancer chemoprevention: an updated Cochrane 
systematic review. Br. J. Urol. 106:1444–1451. https://
doi.org/10.111/j.64-410X.2010.09714.x.
 2. Green, L., D. K. Wysowski, and J. L. Fourcroy. 1996. 
Gynecomastia and breast cancer during finasteride 
therapy. N. Engl. J. Med. 335:823.
 3. Lee, S. C., and R. J. Ellis. 2004. Male breast cancer 
during finasteride therapy. J. Natl Cancer Inst. 
96:338–339.
 4. McConnell, J. D., B. Reginald, W. Patrick, A. Gerald, L. 
Michael, H. H. Logan, et al. 1998. The effect of 
finasteride on the risk of acute urinary retention and 
the need for surgical treatment among men with  
benign prostatic hyperplasia. N. Engl. J. Med. 
338:557–563.
 5. McConnell, J. D., C. G. Roehrborn, O. M. Bautista, G. L. 
Andriole Jr, C. M. Dixon, J. W. Kusek, et al. 2003. The 
long- term effect of doxazosin, finasteride, and combination 
therapy on the clinical progression of benign prostatic 
hyperplasia. N. Engl. J. Med. 349:2387–2398.
 6. MHRA. 2009. The risk of male breast cancer with 
finasteride. MHRA Public Assessment Report 2009.
 7. Shenoy, N. K., and S. M. Prabhakar. 2010. Finasteride 
and male breast cancer: does the MHRA report show a 
link? J. Cutan. Aesthetic Surg. 3:102–105.
 8. Thompson, I. M., P. J. Goodman, C. M. Tangen, M. 
Scott Lucia, G. J. Miller, L. G. Ford, et al. 2003. The 
influence of finasteride on the development of prostate 
cancer. N. Engl. J. Med. 349:215–224.
 9. Kjærulff, T. M., A. K. Ersbøll, A. Green, M. Emneus, E. 
Pukkala, K. Bolin, et al. 2015. Patterns of finasteride 
use in the male populations in four Nordic countries:  
a cross- national drug utilization study. J. Urol. 
50:220–227.
10. Bird, S. T., J. M. Brophy, A. G. Hartzema, J. A. 
Delaney, and M. Etminan. 2013. Male breast cancer and 
5alpha- reductase inhibitors finasteride and dutasteride.  
J. Urol. 190:1811–1814.
260 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
M. Meijer et al.Finasteride Treatment and Male Breast Cancer
11. Duijnhoven, R. G., S. M. Straus, P. C. Souverein, A. de 
Boer, J. R. Bosch, A. W. Hoes, et al. 2014. Long- term 
use of 5alpha- reductase inhibitors and the risk of male 
breast cancer. Cancer Causes Control 25:1577–1582.
12. Miao, H., H. M. Verkooijen, K. S. Chia, C. Bouchardy, 
E. Pukkala, S. Larønningen, et al. 2011. Incidence and 
outcome of male breast cancer: an international 
population- based study. J. Clin. Oncol. 29:4381–4386.
13. Muir, C., J. Waterhouse, T. Mack, J. Powell, and S. 
Whelan. 1987. Cancer incidence in five continents. 
International Agency for Research on Cancer, Lyon.
14. Sasco, A. J., A. B. Lowenfels, and Jong P. Pasker-de. 
1993. Review article: epidemiology of male breast 
cancer. a meta- analysis of published case- control studies 
and discussion of selected aetiological factors. Int. J. 
Cancer 53:538–549.
15. Ewertz, M., L. Holmberg, S. Tretli, B. V. Pedersen, and 
A. Kristensen. 2001. Risk factors for male breast 
cancer–a case- control study from Scandinavia. Acta 
Oncologica (Stockholm, Sweden) 40:467–471.
16. Giordano, S. H., A. U. Buzdar, and G. N. Hortobagyi. 
2002. Breast cancer in men. Ann. Intern. Med. 137:678–687.
17. Gomez-Raposo, C., F. Zambrana Tevar, M. Sereno 
Moyano, M. Lopez Gomez, and E. Casado. 2010. Male 
breast cancer. Cancer Treat. Rev. 36:451–457.
18. Johansen Taber, K. A., L. R. Morisy, A. J. Osbahr III, 
and B. D. Dickinson. 2010. Male breast cancer: risk 
factors, diagnosis, and management (Review). Oncol. 
Rep. 24:1115–1120.
19. Krause, W. 2004. Male breast cancer–an andrological 
disease: risk factors and diagnosis. Andrologia 36:346–354.
20. Weiss, J. R., K. B. Moysich, and H. Swede. 2005. 
Epidemiology of male breast cancer. Cancer Epidemiol. 
Biomark. Prev. 14:20–26.
21. Engholm, G., J. Ferlay, N. Christensen, A. M. T. Kejs, 
R. Hertzum-Larsen, T. B. Johannesen, et al. 2016. 
NORDCAN: Cancer Incidence, Mortality,Prevalence and 
Survival in the Nordic Countries, Version 7.3 
(08.07.2016). Association of the Nordic Cancer 
Registries. Danish Cancer Society. Available from http://
www.ancr.nu (last accessed: August 2016)
22. Brinton, A., M. B. Cook, V. McCormack, K. C. 
Johnson, H. Olsson, J. T. Casagrande, et al. 2014. 
Anthropometric and hormonal risk factors for male 
breast cancer: male breast cancer pooling project results. 
J. Natl Cancer Inst. 106:dtj465.
23. Fentiman, I. S., A. Fourquet, and G. N. Hortobagyi. 
2006. Male breast cancer. Lancet 367:595–604.
24. Lexis macro for splitting person-time in SAS. 2007. 
Available at http://www.bendixcarstensen.com/Lexis/(last 
accessed 1 May 2012)
25. Bryant, E., and D. R. Morganstein. 1987. Sample size 
determination for longitudinal surveys. Proceedings of 
Survey Research Methods Section of the American 
Statistical Association.
26. Gjerstorff, M. L. 2011. The Danish Cancer Registry. 
Scand. J. Public Health 39:42–45.
27. Kildemoes, H. W., H. T. Sorensen, and J. Hallas. 2011. 
The Danish National Prescription Registry. Scand. J. 
Public Health 39:38–41.
28. Pukkala, E. 2011. Biobanks and registers in 
epidemiologic research on cancer. Methods Mol. Biol. 
(Clifton, NJ) 675:127–164.
29. Teppo, L., E. Pukkala, and M. Lehtonen. 1994. Data 
quality and quality control of a population- based cancer 
registry. Experience in Finland. Acta Oncol. (Stockholm, 
Sweden) 33:365–369.
30. Wettermark, B., H. Zoëga, K. Furu, M. Korhonen, J. 
Hallas, M. Nørgaard, et al. 2013. The Nordic 
prescription databases as a resource for 
pharmacoepidemiological research – a literature review. 
Pharmacoepidemiol. Drug Saf. 22:691–699.
31. Furu, K., B. Wettermark, M. Andersen, J. F. 
Martikainen, A. B. Almarsdottir, and H. T. Sørensen. 
2009. The Nordic countries as a cohort for 
pharmacoepidemiological research. Basic Clin. 
Pharmacol. Toxicol. 106:86–94.
Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. Percentage of PY among finasteride users 
out of PY in the total male population in each of the 
four Nordic countries.
